NLG802 + Temozolomide for Brain Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a open label Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of NLG802, an investigational agent intended to inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme, in combination with temozolomide chemotherapy in children with primary brain tumors.
Are You a Good Fit for This Trial?
This trial is for children with progressive brain cancer called diffuse intrinsic pontine glioma (DIPG) or similar primary brain tumors. Participants must be able to take oral medication and meet certain health requirements set by the study team.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- NLG802 (indoximod Prodrug)
- Temozolomide
Trial Overview
The study tests increasing doses of NLG802 (an experimental drug that targets a specific enzyme in cancer cells) taken by mouth, combined with standard chemotherapy temozolomide. The main goal is to check safety and how the body processes these drugs.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Find a Clinic Near You
Who Is Running the Clinical Trial?
Lumos Pharma
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.